Brief: Ipsen SA Says Late-Breaking Analysis Demonstrates Characteristics Associated With Long-Term Overall Survival With Onivyde Regimen In Metastatic Pancreatic Adenocarcinoma
31/05/2025 13:13
May 31 (Reuters) - Ipsen SA IPN.PA: IPSEN SA: LATE-BREAKING ANALYSIS DEMONSTRATES CHARACTERISTICS ASSOCIATED WITH LONG-TERM OVERALL SURVIVAL WITH ONIVYDE REGIMEN IN METASTATIC PANCREATIC ADENOCARCINOMA IPSEN SA: DOSE REDUCTIONS AND/OR TREATMENT DELAYS FOR MANAGEMENT OF ADVERSE EVENTS ENABLED PATIENTS TO STAY ON TREATMENT LONGER IPSEN SA: ANALYSIS OF NAPOLI 3 STUDY DETERMINED CHARACTERISTICS ASSOCIATED WITH LONG-TERM SURVIVAL Source text: ID:nGNE7t3VM6 Further company coverage: IPN.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients